‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。